CME Capital Surpluse from 2010 to 2024

CME Stock  USD 229.37  0.33  0.14%   
CME's Capital Surpluse is increasing over the years with slightly volatile fluctuation. Capital Surpluse is expected to dwindle to about 20.8 B. During the period from 2010 to 2024 CME Capital Surpluse annual values regression line had geometric mean of  19,489,952,067 and mean square error of 1728462.5 T. View All Fundamentals
 
Capital Surpluse  
First Reported
2009-06-30
Previous Quarter
22.3 B
Current Value
22.3 B
Quarterly Volatility
1.9 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CME financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CME's main balance sheet or income statement drivers, such as Depreciation And Amortization of 398.7 M, Interest Expense of 107.7 M or Selling And Marketing Expenses of 1.1 B, as well as many indicators such as Price To Sales Ratio of 8.04, Dividend Yield of 0.0237 or PTB Ratio of 3.8. CME financial statements analysis is a perfect complement when working with CME Valuation or Volatility modules.
  
Check out the analysis of CME Correlation against competitors.

Latest CME's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of CME Group over the last few years. It is CME's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CME's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

CME Capital Surpluse Regression Statistics

Arithmetic Mean19,636,356,333
Geometric Mean19,489,952,067
Coefficient Of Variation12.97
Mean Deviation2,219,500,089
Median17,896,900,000
Standard Deviation2,547,297,701
Sample Variance6488725.6T
Range8.4B
R-Value0.87
Mean Square Error1728462.5T
R-Squared0.75
Significance0.000028
Slope494,152,036
Total Sum of Squares90842158.1T

CME Capital Surpluse History

202420.8 B
202325.5 B
202122.2 B
202021.2 B
201921.1 B
201821.1 B
201717.9 B

About CME Financial Statements

CME stakeholders use historical fundamental indicators, such as CME's Capital Surpluse, to determine how well the company is positioned to perform in the future. Although CME investors may analyze each financial statement separately, they are all interrelated. For example, changes in CME's assets and liabilities are reflected in the revenues and expenses on CME's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CME Group. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse25.5 B20.8 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:
Check out the analysis of CME Correlation against competitors.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Financial Exchanges & Data space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.214
Dividend Share
4.55
Earnings Share
9.51
Revenue Per Share
16.795
Quarterly Revenue Growth
0.185
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.